Amplitude Surgical (AMPLI.PA) Fundamental Analysis & Valuation

EPA:AMPLI • FR0012789667

Current stock price

6.25 EUR
-0.05 (-0.79%)
Last:

This AMPLI.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. AMPLI.PA Profitability Analysis

1.1 Basic Checks

  • AMPLI had positive earnings in the past year.
  • AMPLI had a positive operating cash flow in the past year.
  • In multiple years AMPLI reported negative net income over the last 5 years.
  • Each year in the past 5 years AMPLI had a positive operating cash flow.
AMPLI.PA Yearly Net Income VS EBIT VS OCF VS FCFAMPLI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

1.2 Ratios

  • AMPLI has a Return On Assets of 0.39%. This is in the lower half of the industry: AMPLI underperforms 65.08% of its industry peers.
  • AMPLI has a Return On Equity of 1.15%. This is in the lower half of the industry: AMPLI underperforms 65.08% of its industry peers.
  • With a Return On Invested Capital value of 3.48%, AMPLI is not doing good in the industry: 63.49% of the companies in the same industry are doing better.
  • AMPLI had an Average Return On Invested Capital over the past 3 years of 2.94%. This is significantly below the industry average of 10.21%.
  • The 3 year average ROIC (2.94%) for AMPLI is below the current ROIC(3.48%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.39%
ROE 1.15%
ROIC 3.48%
ROA(3y)4.54%
ROA(5y)0.64%
ROE(3y)11.48%
ROE(5y)-1.81%
ROIC(3y)2.94%
ROIC(5y)N/A
AMPLI.PA Yearly ROA, ROE, ROICAMPLI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • AMPLI has a worse Profit Margin (1.00%) than 60.32% of its industry peers.
  • The Operating Margin of AMPLI (10.22%) is comparable to the rest of the industry.
  • AMPLI's Gross Margin of 79.74% is amongst the best of the industry. AMPLI outperforms 93.65% of its industry peers.
  • In the last couple of years the Gross Margin of AMPLI has grown nicely.
Industry RankSector Rank
OM 10.22%
PM (TTM) 1%
GM 79.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.67%
GM growth 5Y9.09%
AMPLI.PA Yearly Profit, Operating, Gross MarginsAMPLI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. AMPLI.PA Health Analysis

2.1 Basic Checks

  • AMPLI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for AMPLI remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, AMPLI has more shares outstanding
  • AMPLI has a worse debt/assets ratio than last year.
AMPLI.PA Yearly Shares OutstandingAMPLI.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AMPLI.PA Yearly Total Debt VS Total AssetsAMPLI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • AMPLI has an Altman-Z score of 1.42. This is a bad value and indicates that AMPLI is not financially healthy and even has some risk of bankruptcy.
  • AMPLI has a worse Altman-Z score (1.42) than 69.84% of its industry peers.
  • AMPLI has a Debt/Equity ratio of 1.11. This is a high value indicating a heavy dependency on external financing.
  • AMPLI has a Debt to Equity ratio of 1.11. This is amonst the worse of the industry: AMPLI underperforms 84.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Altman-Z 1.42
ROIC/WACC0.48
WACC7.32%
AMPLI.PA Yearly LT Debt VS Equity VS FCFAMPLI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 1.91 indicates that AMPLI should not have too much problems paying its short term obligations.
  • AMPLI has a Current ratio of 1.91. This is in the better half of the industry: AMPLI outperforms 61.90% of its industry peers.
  • A Quick Ratio of 0.94 indicates that AMPLI may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.94, AMPLI is in line with its industry, outperforming 42.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.91
Quick Ratio 0.94
AMPLI.PA Yearly Current Assets VS Current LiabilitesAMPLI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AMPLI.PA Growth Analysis

3.1 Past

  • AMPLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -97.47%.
  • AMPLI shows a small growth in Revenue. In the last year, the Revenue has grown by 4.25%.
  • AMPLI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.67% yearly.
EPS 1Y (TTM)-97.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-245.95%
Revenue 1Y (TTM)4.25%
Revenue growth 3Y8.63%
Revenue growth 5Y0.67%
Sales Q2Q%4.99%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AMPLI.PA Yearly Revenue VS EstimatesAMPLI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
AMPLI.PA Yearly EPS VS EstimatesAMPLI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 0 -0.05 -0.1

More info and screens

Find the best growth stocksShow best growing peers

1

4. AMPLI.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • AMPLI is valuated quite expensively with a Price/Earnings ratio of 312.50.
  • Compared to the rest of the industry, the Price/Earnings ratio of AMPLI indicates a slightly more expensive valuation: AMPLI is more expensive than 63.49% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.78. AMPLI is valued rather expensively when compared to this.
Industry RankSector Rank
PE 312.5
Fwd PE N/A
AMPLI.PA Price Earnings VS Forward Price EarningsAMPLI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AMPLI is valued a bit cheaper than the industry average as 60.32% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.05
AMPLI.PA Per share dataAMPLI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMPLI.PA Dividend Analysis

5.1 Amount

  • AMPLI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AMPLI.PA Fundamentals: All Metrics, Ratios and Statistics

Amplitude Surgical

EPA:AMPLI (10/9/2025, 7:00:00 PM)

6.25

-0.05 (-0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)10-22
Inst Owners0.11%
Inst Owner ChangeN/A
Ins Owners2.47%
Ins Owner ChangeN/A
Market Cap300.13M
Revenue(TTM)108.47M
Net Income(TTM)1.09M
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 312.5
Fwd PE N/A
P/S 2.77
P/FCF N/A
P/OCF 50.58
P/B 3.17
P/tB N/A
EV/EBITDA 16.05
EPS(TTM)0.02
EY0.32%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)0.12
OCFY1.98%
SpS2.26
BVpS1.97
TBVpS-0.86
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.94
Profitability
Industry RankSector Rank
ROA 0.39%
ROE 1.15%
ROCE 4.78%
ROIC 3.48%
ROICexc 3.8%
ROICexgc 10.4%
OM 10.22%
PM (TTM) 1%
GM 79.74%
FCFM N/A
ROA(3y)4.54%
ROA(5y)0.64%
ROE(3y)11.48%
ROE(5y)-1.81%
ROIC(3y)2.94%
ROIC(5y)N/A
ROICexc(3y)3.37%
ROICexc(5y)N/A
ROICexgc(3y)9.91%
ROICexgc(5y)N/A
ROCE(3y)4.01%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.67%
GM growth 5Y9.09%
F-Score7
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Debt/EBITDA 4.25
Cap/Depr 137.68%
Cap/Sales 17.25%
Interest Coverage 250
Cash Conversion 24.04%
Profit Quality N/A
Current Ratio 1.91
Quick Ratio 0.94
Altman-Z 1.42
F-Score7
WACC7.32%
ROIC/WACC0.48
Cap/Depr(3y)129.83%
Cap/Depr(5y)100.73%
Cap/Sales(3y)17.03%
Cap/Sales(5y)14.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-245.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.25%
Revenue growth 3Y8.63%
Revenue growth 5Y0.67%
Sales Q2Q%4.99%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.6%
OCF growth 3Y19.93%
OCF growth 5Y-13.28%

Amplitude Surgical / AMPLI.PA Fundamental Analysis FAQ

What is the fundamental rating for AMPLI stock?

ChartMill assigns a fundamental rating of 2 / 10 to AMPLI.PA.


What is the valuation status for AMPLI stock?

ChartMill assigns a valuation rating of 1 / 10 to Amplitude Surgical (AMPLI.PA). This can be considered as Overvalued.


Can you provide the profitability details for Amplitude Surgical?

Amplitude Surgical (AMPLI.PA) has a profitability rating of 4 / 10.


What is the financial health of Amplitude Surgical (AMPLI.PA) stock?

The financial health rating of Amplitude Surgical (AMPLI.PA) is 1 / 10.